|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -.--% |
|
-.--% | -98.51% |
| 2018 | Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from S&P TMI Index | CI |
| 2018 | Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from NASDAQ Composite Index | CI |
Anthera Pharmaceuticals, Inc. announced the appointment of Steven Engle to and the departure of Dr. James Healy, MD, PhD from its Board of Directors. Mr. Engle has served as the Chief Executive Officer of Averigon Consulting, since 2011. Dr. James Healy has resigned his position as a Director effective March 25, 2014.
Dr. Healy, General Partner of Sofinnova Ventures, joined Anthera's board in 2006.
| 1st Jan change | Capi. | |
|---|---|---|
| -98.51% | 26 | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +3.23% | 22.78B | |
| -10.44% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
ANTHERA PHARMACEUTICALS, INC. 
